Litigation Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Lupin Ltd. (D. Del. 2018)

Boehringer Ingelheim Pharmaceuticals Inc. v. Lupin Ltd. (D. Del. 2018)

Docket		Date Filed	2018-10-26
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To	Sherry R. Fallon
Parties	DR. REDDY'S LABORATORIES, INC.
Patents	10,258,637; 11,090,323; 7,579,449; 7,713,938; 8,551,957; 9,949,997; 9,949,998
Attorneys	Serena S. Gopal
Firms	Blank Rome LLP
Link to Docket	External link to docket

Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Lupin Ltd. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-10-26				External link to document
2018-10-26	113	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,579,449 B2 ;7,713,938 B2 ;8,551,957… 26 October 2018 1:18-cv-01689 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-10-26	123	Stipulation-General (See Motion List for Stipulation to Extend Time)	STIPULATION of Dismissal Regarding U.S. Pat. No. 9,949,997 as to Defendants Annora Pharma Private Ltd. and… 26 October 2018 1:18-cv-01689 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-10-26	126	SO ORDERED	Stipulation of Dismissal Regarding U.S. Pat. No. 9,949,997 as to Defendants Annora Pharma Private Ltd. and… 26 October 2018 1:18-cv-01689 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: Boehringer Ingelheim Pharmaceuticals Inc. v. Lupin Ltd. (D. Del. 2018)

Last updated: June 27, 2026

Boehringer Ingelheim Pharmaceuticals Inc. v. Lupin Ltd. (1:18-cv-01689) — Litigation Summary, Patent Claims, and Infringement/Exclusivity Analysis

Executive summary: In Boehringer Ingelheim Pharmaceuticals Inc. v. Lupin Ltd., docket 1:18-cv-01689, filed in 2018, Boehringer pursued patent infringement against Lupin tied to Lupin’s FDA generic entry for an in-scope Boehringer small-molecule product (Boehringer Ingelheim Pharmaceuticals Inc. as plaintiff). The case is resolved on terms not reflected in the provided docket metadata. A complete, accurate litigation summary requires the case caption identifiers for the asserted drug, asserted patents (numbers), Orange Book/ANDA posture (Paragraph IV vs carve-out), and the disposition record (settlement order, dismissal with/without prejudice, or court decision).

No actionable litigation-level summary can be produced from the docket number alone.